摘要
目的 :探讨甘精胰岛素联合瑞格列奈与精蛋白锌重组赖脯胰岛素混合注射液治疗2型糖尿病的疗效及安全性。方法 :选择我院2016年3月-2017年4月收治的103例2型糖尿病患者为研究对象,按随机数字表法分为对照组与研究组,其中对照组51例,采用精蛋白锌重组赖脯胰岛素混合注射液[0.4 U/(kg·d)]注射治疗,研究组52例采用甘精胰岛素[0.1 U/(kg·d)]联合瑞格列奈(1.0~3.0 mg)治疗,比较两组治疗前后血糖指标变化情况及不良反应发生情况。结果 :治疗后,两组血糖均较治疗前显著降低(P<0.05),且研究组血糖控制效果优于对照组(P<0.05);与对照组比较,研究组日胰岛素使用量少、血糖达标用时短、体质量增加少、夜间低血糖发生次数少,两组比较有统计学差异(P<0.05);研究组不良反应发生率显著低于对照组(P<0.05)。结论 :临床上以甘精胰岛素联合瑞格列奈治疗2型糖尿病较精蛋白锌重组赖脯胰岛素混合注射液控制血糖更平稳,胰岛素使用少,低血糖发生率低,用药安全性高。
Objective:To investigate the efficacy and safety of insulin glargine combined with repaglinide and mixed protamine zinc recombinant human insulin lispro injection in the treatment of type 2 diabetes. Methods:A total of 103 patients with type 2 diabetes were selected in our hospital from March 2016 to April 2017 and the patients were divided into control group and study group by random number table method. The control group(51 cases) was given mixed protamine zinc recombinant human insulin lispro injection [0.4 U/(kg·d)], the study group(52 patients) was given insulin glargine [0.1 U/(kg·d)] combined with repaglinide(1~3 mg) treatment. The changes of blood glucose indexes before and after treatment and the incidence of adverse reactions were compared between the two groups. Results:After treatment, the levels of blood glucose of the two groups were significantly lower than those of before treatment(P<0.05), and the levels of blood glucose of the study group was better than that of the control group(P<0.05). The daily usage amount of insulin of study group was less than that of the control group, the time of reaching target of glucose was shorter, the body mass gain was less and incidence of nocturnal hypoglycemia was less, the difference between the two groups was statistically significant(P<0.05). The incidence of adverse reactions of the study group was significantly lower than that of the control group(P<0.05). Conclusion:Compared with mixed protamine zinc recombinant human insulin lispro injection, insulin glargine combined with repaglinide in the treatment of diabetes was more stable in controlling blood sugar, and with low insulin consumption, low incidence of hypoglycemia, high safety.
出处
《中国执业药师》
CAS
2017年第10期36-38,共3页
China Licensed Pharmacist